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Monocytes leave the blood and enter tissues. In healing wounds and
fibrotic lesions, some of the monocytes differentiate into fibroblast-
like cells called fibrocytes. In healthy tissues, even though monocytes
enter the tissue, for unknown reasons, very few monocytes differ-
entiate into fibrocytes. In this report, we show that fibroblasts from
healthy human tissues secrete the neuronal guidance protein Slit2
and that Slit2 inhibits human fibrocyte differentiation. In mice, injec-
tions of Slit2 inhibit bleomycin-induced lung fibrosis. In lung tissue
from pulmonary fibrosis patients with relatively normal lung func-
tion, Slit2 has a widespread distribution whereas, in patients with
advanced disease, there is less Slit2 in the fibrotic lesions. These data
may explain why fibrocytes are rarely observed in healthy tissues,
may suggest that the relative levels of Slit2 present in healthy tissue
and at sites of fibrosis may have a significant effect on the decision of
monocytes to differentiate into fibrocytes, and may indicate that
modulating Slit2 signaling may be useful as a therapeutic for fibrosis.
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To help form granulation tissue during wound healing, mono-cytes leave the circulation, enter the tissue, and differentiate
into fibroblast-like cells called fibrocytes (1–4). Fibrocytes are
also found in lesions associated with fibrotic diseases such as
pulmonary fibrosis, congestive heart failure, cirrhosis of the liver,
and nephrogenic systemic fibrosis (3, 5–9). Fibrocytes express
markers of both hematopoietic cells (CD34, CD45, FcγR, LSP-1,
and MHC class II) and stromal cells (collagens, fibronectin, and
matrix metalloproteases) (2, 3, 10–12). Fibrocytes also promote
angiogenesis by secreting VEGF, bFGF, IL-8, and PDGF and
promote fibroblast proliferation, migration, and collagen pro-
duction by secreting TGF-β and CTGF (13, 14). Fibrocyte re-
cruitment and differentiation is regulated by a variety of factors
(3, 15). In vitro, monocytes can differentiate into fibrocytes
without the addition of any exogenous factors (5, 11, 12, 16–22).
A key question about fibrocyte differentiation and fibrosis is why,
in healthy tissues where monocytes and macrophages are readily
identified, fibrocytes are rarely observed (3, 8, 23–26).
In tissues, fibroblasts are a major cell population and can
modulate the immune system (27–30). In this report, we show that
fibroblasts secrete the neuronal guidance protein Slit2 and
that Slit2 inhibits fibrocyte differentiation. In addition, we show that
injections of Slit2 reduce bleomycin-induced pulmonary fibrosis in
mice. Finally, we show that, in the mouse pulmonary fibrosis model
as well as human patients with pulmonary fibrosis, there seems to be
a decrease in Slit2 levels in the lungs, suggesting that pulmonary
fibrosis may be in part a Slit2 deficiency disease. These data suggest
that the relative level of Slit2 present at sites of wound healing,
inflammation, and fibrosis may have a profound effect on the ability
of monocytes to differentiate into fibrocytes.
Results
Fibroblasts Inhibit Human Fibrocyte Differentiation. By secreting
collagen and fibronectin, fibrocytes can effectively replace a fi-
broblast (3). In a healthy tissue, there is a sufficient local density
of fibroblasts so no additional fibroblasts (or fibrocytes) would be
needed. To test the hypothesis that fibroblasts might secrete
soluble factors to signal monocytes that have entered the tissue
to not differentiate into fibrocytes, we added conditioned me-
dium from human fibroblasts (FCM) to human peripheral blood
mononuclear cells (PBMCs) in conditions where some of the
monocytes in the PBMCs would normally differentiate into
fibrocytes. The PBMCs were cultured for 5 d in serum-free
medium (SFM) with FCM from human adult skin, adult lung,
and MRC5 fetal lung fibroblasts. In the absence of fibroblast
conditioned medium, we observed 520–1,660 fibrocytes per 105
PBMCs from the different donors, similar to what we and others
have previously observed (10, 11, 18, 31). Because of this vari-
ability, for each donor, fibrocyte numbers were normalized to
serum-free controls. For all donors, compared with the control
with no added FCM, 10% and above FCM significantly inhibited
fibrocyte differentiation (Fig. 1 A–C).
To verify that the FCM was affecting the number of fibrocytes
and to determine whether FCM altered the phenotype of fibro-
cytes, we stained PBMCs after 5 d of culture with or without FCM
for fibrocyte markers (Fig. 1 D–K). In the absence of FCM, the
elongated cells were positive for markers expressed by fibrocytes,
including CD13 and CD45, and had no observable staining for the
macrophage marker CD163. In the presence of 30% FCM, the
number of fibrocytes was significantly reduced although macro-
phages were readily detected, as determined by the expression of
CD13, CD14, and CD163.
Fibroblasts Secrete Slit2, Which Inhibits Fibrocyte Differentiation.
The factor (or factors) secreted by the fibroblasts were stable
when stored for 2 wk at 4 °C or frozen at −20 °C or −80 °C. We
tested the FCM for cytokines known to regulate fibrocyte
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differentiation or involvement in fibrotic responses. We did not
detect any cytokines known to regulate fibrocyte differentiation,
such as IL-4, IL-10, IL-12, IL-13, or IFN-γ (Fig. S1A). We did
detect IL-6, along with low levels of TNF-α, but we have pre-
viously shown that these cytokines do not significantly affect
fibrocyte differentiation (17). To determine if the factor secreted
by fibroblasts was secreted by other cells, we cultured PBMCs in
the presence of 30% (vol/vol) conditioned medium from HEK293
cells, which secrete a wide variety of proteins (32, 33). Compared
with cells cultured in SFM, we found that MRC5-FCM inhibited
fibrocyte differentiation, but HEK293-CM did not (Fig. S1B).
Fractionation with centrifugal filters indicated that the inhibitory
activity secreted by fibroblasts was a factor larger than 100 kDa (Fig.
2A). We then fractionated the FCM by ion exchange chromatog-
raphy (Fig. 2B). The inhibitory factor(s) eluted from an anion ex-
change column as a single peak in fractions 24 (fibrocyte counts
31% of control) and 25 (42.5% of control) whereas the adjacent
fractions 20–23 and 26–31 had fibrocyte counts ∼98% of control.
Using mass spectrometry of tryptic digests, we identified several
components of the active peak (Table S1). Of these proteins, only
albumin and the neuronal repellent factor Slit2 are known to be
extracellular proteins (34). We previously observed that albumin
does not inhibit fibrocyte differentiation (18), suggesting that a
possible candidate for the inhibitory factor in FCM is Slit2.
Recombinant murine Slit2 (rSlit2) protein (97% identity with
human Slit2), corresponding to a 100-kDa portion (Gln26 to
Gln900) of the N-terminal domain of Slit2, inhibited human
(Fig. 3A) and murine (Fig. S2) fibrocyte differentiation. The
rSlit2 IC50 for inhibiting human fibrocyte differentiation was
0.33 ± 0.13 ng/mL, with a Hill coefficient of 0.305 ± 0.08 (mean ±
SEM, n = 3). To determine whether the inhibition of fibrocyte
differentiation by Slit2 is a direct effect on monocytes, or due to
an indirect effect on the B cells, dendritic cells, NK cells, or
T cells, present within the PBMC preparation, we incubated
isolated human monocytes with rSlit2 (Fig. 3A). For all donors,
rSlit2 significantly inhibited fibrocyte differentiation from iso-
lated monocytes, with an IC50 of 0.56 ± 0.13 ng/mL and a Hill
coefficient of 0.41 ± 0.06 (mean ± SEM, n = 3). The IC50 and
Hill coefficient for monocytes was not significantly different
from those of PBMCs (t tests). These data suggest that Slit2 acts
directly on monocytes to inhibit fibrocyte differentiation.
Slit2 binds to the Robo1 receptor on monocytes, macrophages,
neutrophils, and dendritic cells (35–37). We observed that Robo1 is
expressed on fibrocytes and macrophages and that incubating
PBMCs with Slit2 led to reduced fibrocytes, but no obvious changes
in Robo1 levels on macrophages (Fig. S3).
To determine if removal of Slit2 from FCM would alter the
ability of FCM to decrease fibrocyte differentiation, Slit2 was
depleted from FCM using protein G beads coated with anti-Slit2
antibodies. Compared with untreated FCM, removal of Slit2
from MRC5 FCM (Fig. 3B) or dermal FCM (Fig. S4) led to a
significant reduction in the ability of FCM to inhibit human
fibrocyte differentiation. The uncoated beads, and beads coated
with either rabbit IgG or rabbit antibodies against HSP47, did
not significantly alter the inhibition of fibrocyte differentiation by
FCM (Fig. 3B and Fig. S4). These data suggest that Slit2 is the
active factor in FCM that inhibits fibrocyte differentiation.
In the Bleomycin Model, the Early Stages of Inflammation Are Associated
with a Deficiency of Slit2. Bleomycin aspiration leads to epithelial cell
damage, inflammation, collagen deposition, and fibrosis, and these
changes also reduce lung function and peripheral blood oxygen
content (38, 39). BAL fluid from mice at day 3 was collected to
determine if in the early stages of bleomycin-induced inflammation,
there were altered levels of Slit2 protein. In vivo, Slit2 is normally
found as a combination of the full-length protein and several
cleavage products (Fig. S5) (40). In untreated (control) mice, three
major isoforms of Slit2 could be identified (Fig. 4A). In mice that
had aspirated saline alone (NaCl; the buffer solution for the bleo-
mycin), the three isoforms were also readily detected. However, in
the BAL of mice treated with bleomycin, there was a reduction in
the amount of all three isoforms of Slit2 (Fig. 4A). These data in-
dicate that, in the murine bleomycin model of pulmonary fibrosis,
the initial stage is accompanied by a deficiency of endogenous Slit2.
Fig. 1. Fibroblast-secreted factors inhibit fibrocyte differentiation. Human
normal adult (A) lung, (B) dermal, and (C) MRC-5 fetal lung fibroblast con-
ditioned medium (FCM) was collected, and human peripheral blood mono-
nuclear cells (PBMCs) were cultured in the presence or absence of FCM for 5
d. Values are mean ± SEM (n = 5). *P < 0.05 and **P < 0.01 compared with
the no-FCM control (t test). (D–K) PBMCs were cultured for 5 d in (D–G) SFM
or (H–K) 30% MRC-5 FCM. After 5 d, PBMCs were air-dried, fixed, and
stained with antibodies against (D and H) the fibrocyte and macrophage
marker CD13, (E and I) the pan leukocyte marker CD45, (F and J) the mac-
rophage marker CD163, and (G and K) mouse IgG1 antibodies (red staining).
Cells were then counterstained with hematoxylin to identify nuclei (blue).
Photomicrographs are representative results from five different donors. The
spindle-shaped elongated cells are fibrocytes. Arrow points to a fibrocyte,
and * indicates a cluster of macrophages. (Scale bar: 100 μm.)
Fig. 2. Fractionation of FCM and identification of Slit2. (A) FCM was frac-
tionated by centrifugation using 100-kDa filters. PBMCs were cultured for
5 d in the presence or absence of 10% (vol/vol) FCM, 10-fold concentrated
100-kDa retentate (Ret), or 100-kDa flow through (FT). After a 5-d in-
cubation, cells were air-dried, fixed, and stained, and the number of fibro-
cytes was counted. Compared with PBMCs cultured in the absence of con-
ditioned medium (SFM), FCM and the 100-kDa retentate significantly
decreased the number of fibrocytes. Values are mean ± SEM (n = 4). *P <
0.05 and **P < 0.01 (1-way ANOVA, Tukey’s test). (B) Fractions from ion
exchange chromatography of the 100-kDa retentate were analyzed by PAGE
on a 10% reducing gel. M, molecular mass markers with masses in kDa are
indicated at left. The * indicates fractions containing inhibitory activity. The
gel is representative of three independent experiments.
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Slit2 Injections Reduce Bleomycin-Induced Lung Inflammation. Be-
cause fibrocytes participate in fibrosis and Slit2 inhibits fibrocyte
differentiation, we tested the hypothesis that Slit2 might inhibit
fibrosis. After bleomycin aspiration, C57BL/6 mice were treated
with daily i.p. injections of rSlit2 or buffer from day 1–14. To
determine if rSlit2 injections altered the response to bleomycin
aspiration, we measured arterial oxygen saturation (pulse Ox).
At 21 d after bleomycin aspiration, compared with mice that
received saline injections, mice that received rSlit2 injections had
no significant reduction in pulse Ox compared with control mice
(Fig. 4B). Mice were then euthanized. The weakly adhered cells
from the airways were collected by bronchoalveolar lavage
(BAL), and total BAL cells were counted (Fig. 4C). The BAL
cells were also stained for CD11b to identify newly recruited
inflammatory macrophages and neutrophils (Fig. 4D), and
CD11c to identify alveolar macrophages and dendritic cells (Fig.
S6B). As previously observed (38, 39, 41, 42), bleomycin increased
the total number of cells (Fig. 4C), the number of macrophages
and lymphocytes as assessed by morphology (Fig. S6A), and the
percentage of CD11b-positive cells in the BAL (Fig. 4D).
Compared with mice treated with bleomycin and then given PBS
injections, mice treated with bleomycin and then given rSlit2
injections had decreased total number of macrophages, lym-
phocytes, and percentage of CD11b-positive cells in the BAL.
We also observed that the reduction in the percentage of CD11c-
positive cells in the BAL after bleomycin was reversed by Slit2
injections (Fig. S6B).
After BAL, lungs were sectioned and stained with CD45 to
detect interstitial inflammation (Fig. 5 A–D). Bleomycin in-
stillation caused a disruption of the normal lung architecture,
along with areas of inflammatory cell infiltrates (Fig. 5C), and
this inflammation was reduced by rSlit2 injections (Fig. 5D).
Lung sections were also stained to detect other cells that were
not removed by BAL. As previously observed (38, 39, 41, 42),
bleomycin increased the number of CD11b+, CD11c+, and
CD45+ cells in the lungs (Fig. 5E). For mice treated with bleo-
mycin, compared with PBS injections, rSlit2 injections signifi-
cantly reduced the number of CD11b+, CD11c+, and CD45+ cells
in the lungs (Fig. 5E). At 21 d, the presence or absence of
bleomycin, or the presence or absence of rSlit2 injections, did not
significantly alter the numbers of CD3-positive T cells, CD209b
(Sign-R1)-positive dendritic cells, or Ly6G-positive neutrophils
(Fig. 5E). Together, these data indicate that injections of rSlit2
can reduce lung inflammation after bleomycin aspiration.
Slit2 Injections Reduce Bleomycin-Induced Lung Fibrosis. To de-
termine if rSlit2 injections also reduced the bleomycin-induced
fibrotic response, lung sections were stained for collagen-I or
collagen-VI, or stained with picrosirius red to detect collagen. As
previously observed (23, 38, 39), lung collagen levels were in-
creased at 21 d after bleomycin treatment compared with saline
controls (Fig. 6A and Fig. S7). For mice treated with bleomycin,
compared with injections of PBS, injections of rSlit2 significantly
decreased the amount of collagen in the lungs (Fig. 6A and Fig.
S7). Lung sections were also stained for fibrocytes. As previously
observed (5, 23, 43), bleomycin increased the number of fibro-
cytes in the lungs (Fig. 6B). For mice treated with bleomycin,
compared with PBS injections, rSlit2 injections significantly re-
duced the number of fibrocytes in the lungs (Fig. 6B). These data
suggest that, in the murine bleomycin model of pulmonary fi-
brosis, Slit2 injections can reduce fibrosis.
Slit2 Is Expressed by Lung Fibroblasts and Epithelial Cells. Slit2 is
present in the murine fetal lung and also expressed by club cells
(Clara cells) in the adult mouse (44, 45). However, little is known
about the expression of Slit2 by other cells present in human
lung. We observed that human lung fibroblasts and bronchial
epithelial cells produce Slit2 (Fig. S8). These data indicate that
the local production of Slit2 by fibroblasts and epithelial cells
may prevent the differentiation of monocytes into fibrocytes in
normal lung tissue.
Slit2 Levels May Be Abnormally Low in Pulmonary Fibrosis Lesions. To
determine if Slit2 is associated with human lung fibrosis, we ex-
amined the distribution of Slit2 in lung tissue from chronic ob-
structive pulmonary disease (COPD) patients with relatively normal
lungs [>80% forced vital capacity (FVC)] and pulmonary fibrosis
patients with advanced disease (<50% FVC) (Table S2). Lung
tissue from patients with an FVC of >80% showed a widespread
Fig. 3. The effect of recombinant Slit2 (rSlit2) on human fibrocyte differen-
tiation. (A) Human PBMCs and isolated monocytes were cultured in the pres-
ence or absence of rSlit2 for 5 d. Cells were then air-dried, fixed, and stained,
and fibrocytes were counted. Values are mean ± SEM (n = 3). The absence of
error bars indicates that the error was smaller than the plot symbol. rSlit2
concentrations at 0.1 ng/mL and above significantly inhibited fibrocyte dif-
ferentiation (t test). Lines are fits to sigmoidal dose–response curves with
variable Hill coefficients. (B) MRC-5 FCM was incubated with beads labeled
with anti-Slit2 antibodies, anti-HSP-47 (a control protein depletion), rabbit IgG
(a control IgG), or unlabeled beads. Human PBMCs were cultured in the
presence or absence of 10% (vol/vol) antibody-depleted FCM for 5 d. Values
are mean ± SEM (n = 4). *P < 0.05 (1-way ANOVA, Tukey’s test).
Fig. 4. Changes in Slit2 protein, pulse Ox, and BAL cell number after
bleomycin aspiration. (A) BAL from mice was analyzed by Western blotting
using an antibody to the C-terminal portion of Slit2. This antibody detects
the full-length (FL) protein and the 55-, 75-, and 130-kDa fragments. n = 2
naive (Ctrl) mice, n = 3 saline aspiration (NaCl), n = 4 bleomycin aspiration
(Bleo). (B) Mice were assessed for peripheral blood oxygen content (pulse
Ox). (C) The total number of cells collected from the BAL at day 21. (D) The
percentage of CD11b+ inflammatory cells in the BAL at day 21. (B–D) Values
are mean ± SEM (n = 3–4 mice per group). *P < 0.05, **P < 0.01 (1-way
ANOVA, Tukey’s test).
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distribution of Slit2 (Fig. 7). In lung tissue from pulmonary fibrosis
patients with advanced disease, Slit2 distribution was significantly
reduced (Fig. 7H). These data suggest that human pulmonary fi-
brosis may involve a deficiency in Slit2.
Discussion
We found that fibroblast-derived Slit2 inhibits fibrocyte differ-
entiation. In addition, rSlit2 injections inhibit bleomycin-induced
murine lung fibrosis. In human fibrotic lung tissue, we found that
the distribution of Slit2 was widespread, but Slit2 had a restricted
distribution and was apparently absent from the fibrotic areas.
These data suggest that the relative levels of Slit2 present in
normal tissue and at sites of fibrosis may have a significant effect
on the ability of monocytes to differentiate into fibrocytes.
Slit proteins bind a series of receptors called Robo, with
mammals having four receptors, Robo1 to -4 (46, 47). Immune
cells, including monocytes, macrophages, and monocyte-derived
dendritic cells, express Robo receptors (35, 36, 48). In the ner-
vous system, Slit–Robo interactions inhibit the migration of
neuronal cells and prevent axons from recrossing the ventral
midline during development of the CNS (40, 49). Knockouts of
Slit2 and its major receptor Robo1 are embryonic lethal, with
defects in neuronal and lung development (50, 51). Slit2 also
inhibits the migration of neutrophils, dendritic cells, T cells, and
macrophages both in vitro and in vivo (35–37, 45, 52–54).
However, Slit2 promotes eosinophil migration (45), and Slit3
and, to a lesser extent, Slit1 promote monocyte migration (48).
Our results showing that Slit2 inhibits monocyte to fibrocyte
differentiation suggest an additional function for Slit2 in the
innate immune system. In addition, the Slit2 injections may also
regulate the migration of monocytes and/or fibrocyte precursors
entering the lung after bleomycin challenge (3, 55, 56). However,
because the Slit2 injections were systemic, rather than inhaled,
this treatment would not generate a local gradient of Slit2, but
rather inhibit generalized migration. Further work investigating
the local application of Slit2 in the lung is required to determine
the mechanism of action.
Slit2 is present in murine fetal lung and adult rat lung and is
expressed by club cells in the adult mouse (44, 45, 52). However,
little is known about the expression of Slit2 in human lung tissue
during inflammation and fibrosis. Loss of Slit2 mRNA has been
shown to correlate with antibody-induced glomerulonephritis in
the rat (53). The observation that Slit2 is produced by fibroblasts
and epithelial cells suggests that these cells may be an additional
source of antifibrotic molecules in normal lung tissue. In addition,
the loss of Slit2 production may augment profibrotic signals
present in tissues after a fibrotic insult. Whether the reduced
levels of Slit2 seen in human fibrotic tissue is due to a loss of Slit2-
producing cells, such as club cells, or the presence of factors that
down-regulate Slit2 production is unclear. However, the con-
sequences of one or both mechanisms will lead to reduced Slit2
levels and the generation of a profibrotic environment. Together,
our results suggest that Slit2 levels are important in the regulation
of lung inflammation and fibrosis and that therapeutic use of Slit2
may be beneficial in regulating fibrosis.
Materials and Methods
Cell Isolation. Human peripheral blood was collected from healthy adult
volunteers who gave written consent and with specific approval from the
Texas A&M University human subjects Institutional Review Board. Peripheral
blood mononuclear cells (PBMCs) were isolated from blood using Ficoll-
Paque Plus (GE Healthcare Biosciences), as described previously (18). Mono-
cytes were enriched from PBMCs using EasySep monocyte enrichment kits
(StemCell Technologies), as described previously (57). Spleen cells from 4- to
6-wk-old male C57BL/6J mice (The Jackson Laboratory) were isolated as
described previously (19).
Fibroblasts. Human MRC5 fibroblasts (ATCC) and primary human dermal and
lung fibroblasts (Lonza) were grown in RPMI-1640 (Sigma-Aldrich), as de-
scribed previously (27). To make fibroblast conditioned medium (FCM),
∼80% confluent fibroblast cultures in 75-cm2 flasks (BD Bioscience) were
rinsed three times with FibroLife basal medium (LifeLine Cell Technology)
and then incubated in FibroLife basal medium for 2–3 h to remove exoge-
nous serum products. The basal medium was removed, the cells were rinsed
three times with basal medium, and fibroblasts were then cultured in
FibroLife protein-free medium (PFM), containing FibroLife basal medium
supplemented with 10 mM Hepes, 1× nonessential amino acids, 1 mM so-
dium pyruvate, 100 U/mL penicillin, 100 μg/mL streptomycin (all from Sigma-
Aldrich), and 2 mM glutamine (Invitrogen). After 3 d, the medium was col-
lected, clarified by centrifugation at 500 × g for 10 min, and stored at 4 °C.
Clarified conditioned medium was used within 2 d. Conditioned media were
analyzed for cytokines using an ELISArray kit (SABiosciences). HEK293 cells
(Life Technologies) and human lung bronchial epithelial cells (PromoCell)
were cultured following the vendor’s protocol.
Purification and Characterization of Slit2. FCM was fractionated using 100-kDa
cutoff centrifugal filters (AmiconUltra;Millipore) as described previously (23).
Chromatography was performed using an AKTA system (GE Healthcare Bio-
Sciences). Then, 100 mL of FCM was concentrated with a 100-kDa cutoff
centrifugal filter (Amicon) and then washed three times with 10 mL of
10 mM sodium phosphate buffer, pH 7.4 (SB). The retained material was
resuspended in 1 mL of SB and loaded onto a 1-mL anion exchange column
(HiTrap Q; GE Healthcare), and the column was washed extensively in 10 mM
sodium phosphate buffer, pH 7.4, until the absorbance at 280 nm returned
to baseline. Boundmaterial was eluted using 50mL of SB, with a 0- to 1,000-mM
gradient of NaCl. The fractions that inhibited fibrocyte differentiation
Fig. 5. Changes in lung tissue leukocyte populations after bleomycin in-
stillation. Day 21 lungs were stained with antibodies against CD45 to show
cellular inflammation. (A) Lung section after saline aspiration and PBS in-
jections. (B) Lung section after saline aspiration and Slit2 injections. (C) Lung
section after bleomycin aspiration and PBS injections. (D) Lung section after
bleomycin aspiration and Slit2 injections. (Scale bar: 0.1 mm.) (E) Cryo-
sections of mouse lungs were stained with antibodies against CD3 (T cells),
CD11b (neutrophils and inflammatory macrophages), CD11c (resident mac-
rophages and dendritic cells), CD45 (total leukocytes), Ly6G (neutrophils),
and CD209b (Sign-R1 dendritic cells). Values are mean ± SEM (n = 3–4 mice
per group). *P < 0.05, **P < 0.01, ***P < 0.001 (1-way ANOVA, Tukey’s test).
Fig. 6. Changes in lung fibrosis after bleomycin instillation. (A) Day-21 lungs
were stained with picrosirius red to show collagen deposition. The per-
centage area stained with picrosirius red was quantified as a percentage of
the total area of the lung. (B) Lung sections were stained with CD45 and
collagen antibodies, and the number of dual positive fibrocytes was counted.
Values are mean ± SEM (n = 3–4 mice per group). *P < 0.05, **P < 0.01
(1-way ANOVA, Tukey’s test).
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were pooled, concentrated, and desalted using 100-kDa cutoff centrifugal
filters and SB, as described previously (23). Fractions that inhibited fibrocyte
differentiation were digested with trypsin and analyzed at the Mass Spec-
trometry and Proteomics Core Facility, University of Utah, Salt Lake City.
Immunodepletion of Slit2 was performed as described previously (11).
Briefly, 0.5 mL of FCM was incubated overnight at 4 °C with a 0.1-mL packed
volume of protein G magnetic beads (Life Technologies), coated with 100 μg
of rabbit anti-Slit2 antibodies (Epitomics/Abcam), rabbit anti-HSP-47 (Epito-
mics/Abcam) as a control, rabbit IgG (Jackson ImmunoResearch) as a control,
or unlabeled beads. Beads were then removed by magnetic separation, and
the immunodepleted FCM was added to cells.
Fibrocyte Differentiation Assays. Human and murine cells were cultured in
FibroLife SFM, as described previously (18), in the presence or absence of FCM
or recombinant murine Slit2 (R&D Systems). After 5 d, plates were air-dried,
fixed, and stained, and fibrocytes were identified as described previously
(11, 18).
Bleomycin-Induced Lung Inflammation. This study was carried out in accor-
dance with the recommendations in the Guide for the Care and Use of
Laboratory Animals (58) of the National Institutes of Health. The protocol
was approved by the Texas A&M University Animal Use and Care Committee.
All procedures were performed under anesthesia, and all efforts were made
to minimize suffering. To induce fibrosis, 4- to 6-wk-old C57BL/6 mice (The
Jackson Laboratory) were treated with an oropharyngeal aspiration of 50 μL
of 3 U/kg bleomycin (EMD Millipore) in 0.9% saline or saline alone, as de-
scribed previously (39, 41, 42, 59). Starting 24 h after bleomycin aspiration,
mice were given daily i.p. injections of 2 μg of recombinant mouse Slit2 (R&D
Systems) in 0.05 mL of PBS, or PBS alone, from day 1–14 after bleomycin as-
piration (13 d total). Mice were euthanized 21 d after bleomycin aspiration,
and bronchoalveolar lavage (BAL) cells were collected and counted, and
cytospins were prepared as described previously (39, 41, 42, 60). After BAL,
lungs were inflated with and embedded in optimal cutting temperature
(OCT) compound (VWR), frozen, and stored as described previously (23, 39).
Immunohistochemistry and Western Blotting. PBMCs, fibroblasts, or lung ep-
ithelial cells, were cultured for 5 d on eight-well glass microscope slides
(Millipore) and then fixed and stained as described previously (12). The PBMCs
were stained with mouse monoclonal antibodies to CD13 (clone WM15; BD
Biosciences) to detect monocyte-derived cells and fibroblasts, CD45 (clone
HI30, BioLegend) to detect all leukocytes, CD163 (clone GHI/61; BioLegend)
to detect the scavenger receptor for the hemoglobin–haptoglobin complex
expressed by macrophages, or isotype-matched irrelevant mouse mono-
clonal antibodies (BioLegend). Human lung tissue sections were obtained
from the National Heart, Lung and Blood Institute-sponsored Lung Tissue
Research Consortium (LTRC) (Table S2). Fibroblasts, lung epithelial cells, or
lung-tissue sections were prepared and stained with rabbit polyclonal anti-
bodies to Slit2 N-terminal fragment (ab7665; Abcam), as described pre-
viously (12). Isotype-matched rabbit anti-chicken IgY antibodies (Bethyl
Laboratories) were used as controls. Secondary F(ab′)2 biotin-conjugated
donkey anti-mouse or donkey anti-rabbit antibodies were from Jackson
ImmunoResearch. Lung-tissue sections stained with Slit2 antibodies were
analyzed with ImageJ software (61). The percentage area of lung tissue
stained with Slit2 antibodies was quantified as a percentage of the total
area of the lung tissue, as described previously (23). BAL cytospins and fro-
zen lung-tissue sections (5 μm) were prepared, and immunochemistry was
performed as described previously (39). Antibodies to Ly6G (BioLegend)
were used to detect neutrophils, CD3 (BioLegend) to detect T cells, CD11b
(BioLegend) to detect blood and inflammatory macrophages, CD11c (MBL
International) to detect resident lung macrophages and dendritic cells, CD45
(BioLegend) to detect all leukocytes, and CD209b (eBioScience) to detect
SIGN-R1–positive dendritic cells. Isotype-matched rat irrelevant antibodies were
used as controls. Lung sections were also stained with rabbit antibodies to col-
lagen-I (Abcam), collagen VI (Novus Biologicals), IgY, or sirius red to identify
collagen, as described previously (39). To detect fibrocytes, murine lung-tissue
sections were stained for CD45 and collagen-I or collagen-VI, as described pre-
viously (12, 23). Staining was revealed with DyLight488-conjugated goat anti-rat
antibodies (Novus), biotin-conjugated donkey anti-rabbit antibodies (Jackson
ImmunoResearch), and streptavidin–Alexa-647 (Invitrogen). Coverslips were
mounted with fluorescent mounting medium containing DAPI (Vector Labora-
tories). Immunofluorescence images were captured on an Olympus FV1000
confocal microscope and analyzed using Olympus Fluoview software.
Statistical Analysis. Statistical analysis was performed using Prism (GraphPad
Software). Statistical significance between two groups was determined by t
test, or between multiple groups using analysis of variance (ANOVA). Sig-
nificance was defined as P < 0.05.
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